Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET

Company Participants

Juan Sanchez – Vice President-Corporate Communications and Investor Relations

Sharon Mates – Chairman and Chief Executive Officer

Mark Neumann – Chief Commercial Officer

Larry Hineline – Chief Financial Officer

Suresh Durgam – Chief Medical Officer

Conference Call Participants

Vardhman Chhajed – JPMorgan

Leonid Timashev – RBC Capital Markets

Andrew Tsai – Jefferies

Charles Duncan – Cantor Fitzgerald

Jeff Hung – Morgan Stanley

Sumant Kulkarni – Canaccord Genuity

Marc Goodman – SVB Leerink

Umer Raffat – Evercore ISI

Jason Gerberry – Bank of America

Ash Verma – UBS

David Amsellem – Piper Sandler

Corinne Jenkins – Goldman Sachs

Graig Suvannavejh – Mizuho Securities

Operator

Good morning and welcome to Intra-Cellular Therapies First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference call is being recorded.

I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Sanchez

Good morning and thank you all for being here today. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Larry Hineline, Chief Financial Officer. As a reminder, during today’s call, we will be making certain forward-looking statements.

These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that might cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligations to update such statements.

I will now turn the call over to Sharon.

Sharon Mates

Thanks, Juan. Good morning everyone, and welcome to today’s call. Following a strong performance last year, 2023 is off to a great start. During the first quarter, our team delivered strong growth for CAPLYTA and made important progress on the clinical development front. Just a few weeks ago, we announced robust positive top line results from Study 403, evaluating lumateperone in patients with major depressive disorder, or MDD, exhibiting mixed features and in patients with bipolar depression exhibiting mixed features. I will talk more about this in a moment.